Mas receptor activation facilitates innate hematoma resolution and neurological recovery after hemorrhagic stroke in mice.

Abstract

BACKGROUND:

Intracerebral hemorrhage (ICH) is a devastating neurological disease causing severe sensorimotor dysfunction and cognitive decline, yet there is no effective treatment strategy to alleviate outcomes of these patients. The Mas axis-mediated neuroprotection is involved in the pathology of various neurological diseases, however, the role of the Mas receptor in the setting of ICH remains to be elucidated.

METHODS:

C57BL/6 mice were used to establish the ICH model by injection of collagenase into mice striatum. The Mas receptor agonist AVE0991 was administered intranasally (0.9 mg/kg) after ICH. Using a combination of behavioral tests, Western blots, immunofluorescence staining, hematoma volume, brain edema, quantitative-PCR, TUNEL staining, Fluoro-Jade C staining, Nissl staining, and pharmacological methods, we examined the impact of intranasal application of AVE0991 on hematoma absorption and neurological outcomes following ICH and investigated the underlying mechanism.

RESULTS:

Mas receptor was found to be significantly expressed in activated microglia/macrophages, and the peak expression of Mas receptor in microglia/macrophages was observed at approximately 3-5 days, followed by a subsequent decline. Activation of Mas by AVE0991 post-treatment promoted hematoma absorption, reduced brain edema, and improved both short- and long-term neurological functions in ICH mice. Moreover, AVE0991 treatment effectively attenuated neuronal apoptosis, inhibited neutrophil infiltration, and reduced the release of inflammatory cytokines in perihematomal areas after ICH. Mechanistically, AVE0991 post-treatment significantly promoted the transformation of microglia/macrophages towards an anti-inflammatory, phagocytic, and reparative phenotype, and this functional phenotypic transition of microglia/macrophages by Mas activation was abolished by both Mas inhibitor A779 and Nrf2 inhibitor ML385. Furthermore, hematoma clearance and neuroprotective effects of AVE0991 treatment were reversed after microglia depletion in ICH.

CONCLUSIONS:

Mas activation can promote hematoma absorption, ameliorate neurological deficits, alleviate neuron apoptosis, reduced neuroinflammation, and regulate the function and phenotype of microglia/macrophages via Akt/Nrf2 signaling pathway after ICH. Thus, intranasal application of Mas agonist ACE0991 may provide promising strategy for clinical treatment of ICH patients.

• Authors: Xiangyang Deng, Junwei Ren, Kezhu Chen, Jin Zhang, Quan Zhang, Jun Zeng, Tianwen Li, Qisheng Tang, Jian Lin, Jianhong Zhu
• Journal: Journal of neuroinflammation (J Neuroinflammation) Vol. 21 Issue 1 Pg. 106 (Apr 24 2024) ISSN: 1742-2094 [Electronic] England
• PMID: 38658922 (Publication Type: Journal Article)
• Copyright: © 2024. The Author(s).

Chemical References

• Receptors, G-Protein-Coupled
• Proto-Oncogene Proteins

Topics

• Animals
• Mice
• Mice, Inbred C57BL
• Hematoma (drug therapy, pathology, metabolism)
• Male
• Hemorrhagic Stroke (pathology, drug therapy)
• Receptors, G-Protein-Coupled (agonists, metabolism)
• Recovery of Function (drug effects, physiology)
• Proto-Oncogene Proteins (metabolism)
• Brain Edema (etiology, metabolism, drug therapy)
• Microglia (drug effects, metabolism)